For instance, MYCN amplification in high-risk neuroblastoma patients is associated with poor survival; meanwhile, non-amplified MYCN neuroblastoma with low-stage or even metastases can differentiate into benign subtypes or regress spontaneously by apoptosis. This evidence concerns the gene MYCN and neuroblastoma.